Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928156 · ClinicalTrials.gov registry record · NA
Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
NCT05928156: Completed NA study, sponsored by Duke University.
NCT05928156 is a NA study that has completed, run by Duke University. The registered enrollment target is 77 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05928156, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of evidence-informed mobile apps, Myeloma Coach and CLL Coach. These apps have been developed to help manage the physical and emotional symptoms experienced by multiple myeloma and chronic lymphocytic leukemia survivors. This study hopes to determine if a mobile app is a useful tool to help people manage commonly reported symptoms related to Multiple Myeloma (MM) and chronic lymphocytic leukemia (CLL).
Primary Outcome
The ESAS is a validated 10 item survey index used to assessed symptoms. The total ranges from 0 to 60, with a higher score indicating higher physical symptom burden.
Interventions
- OTHER Myeloma Coach or CLL Coach Mobile App
- OTHER Springboard Beyond Cancer informational website
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2021-09-19 |
| Phase | NA |
What the finished NCT05928156 record still lists
NCT05928156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Myeloma Coach or CLL Coach Mobile App is the first listed.
NCT05928156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05928156 about?
NCT05928156 is a clinical study titled "Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT". The purpose of this study is to test the effectiveness of evidence-informed mobile apps, Myeloma Coach and CLL Coach. These apps have been developed to help manage the physical and emotional symptoms experienced by multiple myeloma and chronic lymphocytic leukemia survivors. This study hopes to dete...
What is the current status of trial NCT05928156?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2020-12-17. Estimated completion is 2021-09-19.
What interventions are being tested in trial NCT05928156?
The interventions under investigation include: Myeloma Coach or CLL Coach Mobile App (OTHER), Springboard Beyond Cancer informational website (OTHER).
Who is sponsoring clinical trial NCT05928156?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05928156's enrollment target sits among peer trials
77 1062nd of 2000 higher than 939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI